Venture Capital Firms Looking For Plan B
Executive Summary
Companies are cheap, but money is expensive. Burn must be slowed, but without sacrificing value drivers. And finding the exit has never been more difficult. Can venture investors make the best of the worst of times
You may also be interested in...
Genentech Exec Heads East To Take The Reins Of Cancer-Focused Start-up Agios
Calling it “the right time and the right opportunity,” Genentech’s cancer drug development expert David Schenkein plans to move on.
VCs Think Twice About Type 2 Diabetes Investments
Venture capitalists are reevaluating type 2 diabetes investments in light of daunting new regulatory hurdles and an economic climate that limits their ability to cash out of such companies in a timely fashion. But, say some VCs, truly innovative compounds may be worth the bigger R&D bills and longer time to exit given the dazzlingly large market at stake
VCs Think Twice About Type 2 Diabetes Investments
Venture capitalists are reevaluating type 2 diabetes investments in light of daunting new regulatory hurdles and an economic climate that limits their ability to cash out of such companies in a timely fashion. But, say some VCs, truly innovative compounds may be worth the bigger R&D bills and longer time to exit given the dazzlingly large market at stake